Literature DB >> 2378978

High frequency of human T-cell leukemia-lymphoma virus type II infection in New Mexico blood donors: determination by sequence-specific oligonucleotide hybridization.

B Hjelle1, R Scalf, S Swenson.   

Abstract

The Albuquerque branch of the United Blood Services system was found to have an unusually high blood donor human T-cell leukemia/lymphoma virus (HTLV) seroprevalence (0.72 per 1,000). Many studies investigating HTLV seroprevalence and transmission have assumed that all seropositivity is due to HTLV type I (HTLV-I); recent data dispute this conclusion. We investigated the high prevalence of HTLV seropositivity in New Mexico by determining whether HTLV-I or HTLV-II is predominant in our donors. Using polymerase chain reaction (PCR) amplification of proviral DNA from peripheral blood, followed by sequence-specific hybridization with oligonucleotide probes to distinguish the two viruses, we demonstrate that 9 of 10 Western blot-confirmed HTLV-seropositive blood donors from New Mexico are infected with HTLV-II. Implications of this finding for donors and the safety of the blood supply are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2378978

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.

Authors:  L D Papsidero; R P Dittmer; L Vaickus; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

Review 2.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

3.  Sensitive and specific polymerase chain reaction assays for diagnosis of human T-cell lymphotropic virus type I (HTLV-I) and HTLV-II infections in HTLV-I/II-seropositive individuals.

Authors:  W Heneine; R F Khabbaz; R B Lal; J E Kaplan
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

4.  Comparison of six commercial human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay kits for detection of antibody to HTLV-I and -II.

Authors:  C Cossen; S Hagens; R Fukuchi; B Forghani; D Gallo; M Ascher
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

Review 5.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

6.  High frequencies of human T-lymphotropic virus type I (HTLV-I) infection and presence of HTLV-II proviral DNA in blood donors with anti-thyroid antibodies.

Authors:  H Mine; H Kawai; K Yokoi; M Akaike; S Saito
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

7.  Identification and characterization of a new and distinct molecular subtype of human T-cell lymphotropic virus type 2.

Authors:  N Eiraku; P Novoa; M da Costa Ferreira; C Monken; R Ishak; O da Costa Ferreira; S W Zhu; R Lorenco; M Ishak; V Azvedo; J Guerreiro; M P de Oliveira; P Loureiro; N Hammerschlak; S Ijichi; W M Hall
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

8.  Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus types I and II.

Authors:  B D Roberts; S K Foung; J J Lipka; J E Kaplan; K G Hadlock; G R Reyes; L Chan; W Heneine; R F Khabbaz
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

9.  Isolation and characterization of simian T-cell leukemia virus type II from New World monkeys.

Authors:  Y M Chen; Y J Jang; P J Kanki; Q C Yu; J J Wang; R J Montali; K P Samuel; T S Papas
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Genetic heterogeneity in human T-cell leukemia/lymphoma virus type II.

Authors:  D K Dube; M P Sherman; N K Saksena; V Bryz-Gornia; J Mendelson; J Love; C B Arnold; T Spicer; S Dube; J B Glaser
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.